Susana Rives Solà
Investigador
Research group
Researcher Susana Rives graduated in Medicine in 1994 from the University of Barcelona and received her Doctor of Medicine degree from the University of Barcelona in 2013.
Between 1995 and 1998 she specialized in Hematology and Hemotherapy at the Hospital Clínic de Barcelona.
She spent two stays at prestigious children's leukemia centers in the United States, in 2001 at Saint Jude Research Children's Hospital in Memphis and Children's Hospital of Philadelphia in 2014 where she trained in CAR-T at the Cell Therapy Service with the Dr. Stephen Grupp and Dr. Shannon Maude.
Since 2014 she has been teaching at the University of Barcelona in the Master of Biomedicine in Therapy and translational research in cancer. Block: Leukemia and lymphomas and in the Master's Degree in Pediatric Nursing. Block: Childhood cancer. In 2020 she is the coordinator of the CAR-T Indications block and patient evaluation in the University Specialization Diploma in CAR-T Therapies for hospital pharmacists and hematologists.
In 2000 she joined the Pediatric Hematology Service of the Sant Joan de Déu Hospital in Barcelona. Since 2019 she has been Head of the Leukemia and Lymphoma Functional Unit and coordinator of the CAR-T Multidisciplinary Therapy Team.
Coordinates with Dr. José Luis Dapena, the Leukemia Group of the SEHOP (Spanish Society of Pediatric Hematology and Oncology).
She is currently a principal investigator in 7 clinical trials with immunotherapy and CAR-T. She participated in the first CAR-T clinical trial in Spain, the ELIANA trial, and passed the FDA (U.S. Medication Agency) inspection that contributed to the FDA's approval of Tisagenlecleucel. Dr. Rives belongs to the CAR-T Expert Group of the Ministry of Health and participates in the Case Assessment Committee for CAR-T indication. She is the co-author of the Tisagenlecleucel Pharmaco-Clinical Protocol in pediatric and young adults. She is also a member of the CAR-T expert committee of the Catalan Health Service. She is a member of the DSMB Steering Committee of the CAR-T Front-End Clinical Trial (CCTL0192201J (EudraCT 2017-002116-14)).
She is the author of the publication of the results of the international study of tisagenlecleucel on pediatric LLA in the New England Journal of Medicine (Maude SL, Laetsch TW, Buechner, Rives S, Boyer M, Bittencourt H, et al. N Engl J Med 2018; 378: 439-448).
Professional network profiles
Related websites
Last Publications
- Ruiz-Llobet A, Gassiot S, Sarrate E, Zubicaray J, Rives-Solà S, Suleman W and Berrueco R Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia. THROMBOSIS AND HAEMOSTASIS . 124(10): 973-985.
- Pennesi E, Brivio E, Ammerlaan ACJ, Jiang Y, Van der Velden VHJ, Beverloo HB, Sleight B, Locatelli F, Brethon B, Rossig C, Engstler G, Nilsson A, Bruno B, Petit A, Bielorai B, Rizzari C, Rialland F, Rubio-San-Simón A, Sirvent FJB, Diaz-de-Heredia C, Rives-Solà S and Zwaan CM Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22(+) acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial. HAEMATOLOGICA . 109(10): 3157-3166.
- Wu JH, Pennesi E, Bautista F, Garrett M, Fukuhara K, Brivio E, Ammerlaan ACJ, Locatelli F, van der Sluis IM, Rossig C, Chen-Santel C, Bielorai B, Petit A, Starý J, Díaz-de-Heredia C, Rives-Solà S, O'Marcaigh A, Rizzari C, Engstler G, Nysom K, Rubio-San-Simón A, Bruno B, Bertrand Y, Brethon B, Rialland F, Plat G, Dirksen U, Sramkova L, Zwaan CM and Huitema ADR Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059. CLINICAL PHARMACOKINETICS . 63(7): 981-997.
Projects
- Project name:
- Análisis de los factores pronósticos de fracaso del tratamiento tras terapia con células T con receptores antigénicos quiméricos (CAR-T) en pacientes pediátricos con leucemia linfoblástica aguda de línea B
- Leader
- Susana Rives Solà, Montserrat Torrebadell Burriel
- Funding entities:
- Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD
- Code
- PI21/00218
- Starting - finishing date:
- 2022 - 2026
- Project name:
- Estudio multicéntrico fase 2 en pacientes pediátricos (0-18 años) con leucemia linfoblástica aguda B CD19+ en recaída o refractaria
- Leader
- Susana Rives Solà
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- ICI21/00033
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Desarrollo de una nueva terapia CAR-T dirigida a CD1a para el tratamiento de leucemias/linfomas de células T CD1a+
- Leader
- Susana Rives Solà
- Funding entities:
- Ministerio De Ciencia E Innovacion
- Code
- CPP2021-008508
- Starting - finishing date:
- 2022 - 2025
News
-
The hidden cells behind B-cell acute lymphoblastic leukemia relapse spotlighted for the first time
Drs. Susana Rives, Montserrat Torrebadell and Nerea Vega (IRSJD) participate in a study led by Dr. Pablo Menéndez, group leader at the Josep Carreras Leukaemia Research Institut, who has identified a previously noticed population of pre-leukemic cells might be responsible for some relapses in B-cell acute lymphoblastic leukemia (B-ALL).
More activities
-
Defensa tesi doctoral: Montserrat Mesegué Medà
Auditori Plaza, Hospital Sant Joan de Déu · Online